Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study

The Lancet

Volumn 377, Issue 9768, 2011, Pages 813-822

  Fizazi, Karim ^a   Carducci, Michael ^b   Smith, Matthew ^c   Damião, Ronaldo ^d   Brown, Janet ^e   Karsh, Lawrence ^f   Milecki, Piotr ^g   Shore, Neal ^h   Rader, Michael ⁱ   Wang, Huei ^j   Jiang, Qi ^j   Tadros, Sylvia ^j   Dansey, Roger ^j   Goessl, Carsten ^j  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f Urology Center of Colorado   (United States)

^g GREATER POLAND CANCER CENTRE   (Poland)

^h Carolina Urologic Research Center   (United States)

ⁱ Nyack Hospital   (United States)

^j AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DENOSUMAB; PLACEBO; PROSTATE SPECIFIC ANTIGEN; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; APPETITE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASTRATION; CONSTIPATION; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; NAUSEA; PATHOLOGIC FRACTURE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPINAL CORD COMPRESSION; VITAMIN SUPPLEMENTATION;

EID: 79952360832     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62344-6     Document Type: Article

References (33)

1. A Jemal, R Siegel, J Xu, E Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. J Ferlay, DM Parkin, E Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
3. KL Schulman, J Kohles Economic burden of metastatic bone disease in the U.S. Cancer 109 2007 2334 2342 (Pubitemid 46801565)
4. F Saad, DM Gleason, R Murray for the Zoledronic Acid Prostate Cancer Study Group A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
5. F Saad, DM Gleason, R Murray and for the Zoledronic Acid Prostate Cancer Study Group Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882 (Pubitemid 38807610)
6. MP Roudier, C Morrissey, LD True, CS Higano, RL Vessella, SM Ott Histopathological assessment of prostate cancer bone osteoblastic metastases J Urol 180 2008 1154 1160
7. JE Brown, RJ Cook, P Major Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 2005 59 69
8. LM Demers Bone markers in the management of patients with skeletal metastases Cancer 97 2003 874 879 (Pubitemid 36125826)
9. RC Percival, GH Urwin, S Harris Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption Eur J Surg Oncol 13 1987 41 49 (Pubitemid 17040425)
10. WJ Boyle, WS Simonet, DL Lacey Osteoclast differentiation and activation Nature 423 2003 337 342 (Pubitemid 40852708)
11. K Fizazi, J Yang, S Peleg Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts Clin Cancer Res 9 2003 2587 2597 (Pubitemid 36842101)
12. J Zhang, J Dai, Z Yao, Y Lu, W Dougall, ET Keller Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone Cancer Res 63 2003 7883 7890 (Pubitemid 37466723)
13. K Fizazi, A Lipton, X Mariette Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 27 2009 1564 1571
14. Novartis Zometa (zoledronic acid) package insert 2009 Novartis East Hanover, NJ http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf (accessed Feb 7, 2011).
15. HM James Hung, SJ Wang, Y Tsong, J Lawrence, RT O'Neil Some fundamental issues with non-inferiority testing in active controlled trials Stat Med 22 2003 213 225 (Pubitemid 36163582)
16. PK Anderson, RD Gill Cox's regression model for counting processes: a large sample study Ann Statistics 10 1982 1100 1120
17. PH Westfall, RD Tobias, D Rom, RD Wolfinger, Y Hochberg Multiple comparisons and multiple tests, using the SAS system 1999 SAS Institute Cary, NC
18. RJ Lee, PJ Saylor, MR Smith Treatment and prevention of bone complications from prostate cancer Bone 48 2011 88 95
19. EJ Small, MR Smith, JJ Seaman, S Petrone, MO Kowalski Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer J Clin Oncol 21 2003 4277 4284 (Pubitemid 46621802)
20. K Olson, C Van Poznak Significance and impact of bisphosphonate-induced acute phase responses J Oncol Pharm Pract 13 2007 223 229
21. GK Ellis, HG Bone, R Chlebowski Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 2008 4875 4882
22. A Lipton, GG Steger, J Figueroa Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases J Clin Oncol 25 2007 4431 4437 (Pubitemid 350013849)
23. MR Smith, B Egerdie, N Hernández Toriz Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745 755
24. C Walter, B Al-Nawas, KA Grötz Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate Eur Urol 54 2008 1066 1072
25. DP Dearnaley, MD Mason, MKB Parmar, K Sanders, MR Sydes Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials Lancet Oncol 10 2009 872 876
26. F Saad New research findings on zoledronic acid: survival, pain, and anti-tumour effects Cancer Treat Rev 34 2008 183 192 (Pubitemid 351384327)
27. HI Scher, S Halabi, I Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group J Clin Oncol 26 2008 1148 1159
28. K Fizazi, CN Sternberg, JM Fitzpatrick, RW Watson, M Tabesh Role of targeted therapy in the treatment of advanced prostate cancer BJU Int 105 2010 748 767
29. ND James, A Caty, M Borre Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial Eur Urol 55 2009 1112 1123
30. K Fizazi, P Beuzeboc, J Lumbroso Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer J Clin Oncol 27 2009 2429 2435
31. S Nilsson, L Franzén, C Parker Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 2007 587 594 (Pubitemid 46995621)
32. Henry D, Costa L, Goldwasser F, et al. A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (in press).
33. AT Stopeck, A Lipton, JJ Body Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 2010 5132 5139